Recent advances in age-related metabolic dysfunction-associated steatotic liver disease - PubMed (original) (raw)

Review

Qian-Jun He et al. World J Gastroenterol. 2024.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the world's population and has become a leading cause of chronic liver disease. In recent years, an increasing amount of data suggests that MASLD is associated with aging. As the population ages, age-related MASLD will become a major global health problem. Targeting an aging will become a new approach to the treatment of MASLD. This paper reviews the current studies on the role of aging-related factors and therapeutic targets in MASLD, including: Oxidative stress, autophagy, mitochondrial homeostasis, bile acid metabolism homeostasis, and dysbiosis. The aim is to identify effective therapeutic targets for age-related MASLD and its progression.

Keywords: Aging; Bile acid homeostasis; Dysbiosis; Metabolic dysfunction-associated steatotic liver disease; Mitochondrial homeostasis.

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Figures

Figure 1

Figure 1

Signaling pathways of proliferator-activated receptor alpha and thyroid hormone receptor-beta and drugs targeting these pathways. PPAR: Proliferator-activated receptor; TG: Triglyceride; FFA: Free fatty acid; ACS: Acyl coenzyme A synthetase; FA CoA: Fatty acyl coenzyme A; TCA: Tricarboxylic acid cycle; RXR: Retinoid X receptor; PPRE: PPAR reaction element; THR: Thyroid hormone receptor-beta; LDL: Low-density lipoprotein; LDL-R: Low-density lipoprotein receptor; VLDL: Very low-density lipoprotein.

Figure 2

Figure 2

Targets related to lipids, bile acids, glucose homeostasis and intestinal microbiota in age-related metabolic dysfunction-associated steatotic liver disease. GM: Gut microbiota; FXR: Farnesoid X receptor; RXR: Retinoid X receptor; FXRE: FXR reaction element; FGF19: Fibroblast growth factor 19; FGFR4: Fibroblast growth factor receptor 4; TGR5: Takeda G protein–coupled receptor 5; GLP-1: Glucagon-like peptide-1.

References

    1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186:243–278. - PubMed
    1. National Institutes of Health. National Institute on Aging, Global Health & Aging 2011. Available from: https://www.nia.nih.gov/research/publication/global-health-and-aging/hea... .
    1. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130:223–233. - PubMed
    1. Huang W, Hickson LJ, Eirin A, Kirkland JL, Lerman LO. Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol. 2022;18:611–627. - PMC - PubMed
    1. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–922. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources